Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (32769)	10/29/2009 4:15:30 PM
From: Arthur Radley	Respond to of 52153

Peter, Must admit the PR wasn't very clear on the points you raise, however, they have their Q report coming out next week and maybe they will clarify some of these issues. My understand, this is a totally new program(they are due to report trial results at ASH for another solid tumor application that they are developing with no partner involved) and MITI will incur the expense for this new indication(?) until it enters clinical trials......then the expense will be borne by Sanofi. I would like to think that SNY and MITI have some indication how the antibodes work, based on the promised results due out in 4 weeks. $12M is $12M---and with it just being at this stage I think its a decent amount of money for SNY to invest. ASH is be a key.......IMO!

To: Biomaven who wrote (32769)	10/29/2009 5:25:36 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 52153

corporate-ir.net Today's BIO conference presentation is now available....some highlights: 1) 5 Antibodes in Clinical Trials 2) SNY deal is with undisclosed indication as is the Bayer deal.(He implied that they had numerous other indications that will be available for partnering in the future. 3) "Lot of Data at ASH in December" 4) In discussion with FDA to move MT-103 into pivotal trials to speed to market the drug for this minor indication. 5) They are shooting for 6 months durability in data to be presented at ASH..anything above 6 months would be huge positive for drug. The stock opened this morning will minor bounce, but timed with the SF presentation the stock really bounced on increased volume........ASH will be interesting.